表紙
市場調査レポート

髄芽腫 : パイプライン分析

Medulloblastoma - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 229773
出版日 ページ情報 英文 96 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.02円で換算しております。
Back to Top
髄芽腫 : パイプライン分析 Medulloblastoma - Pipeline Review, H1 2016
出版日: 2016年06月08日 ページ情報: 英文 96 Pages
概要

髄芽腫は子供に最もよく見られる悪性の脳腫瘍で、定義上、小脳に発生します。症状としては、朝頭痛がするものの、時間が経つにつれて改善されます。また、無気力や吐き気、歩行困難、バランスが取れないといったことも起きます。髄芽腫は中枢神経系の他の部位にも広がることがあります。治療としては、化学療法、手術、生物療法、放射線治療などがあります。

当レポートでは、髄芽腫の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、休止中のプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

髄芽腫 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明な製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • Bayer AG
  • DelMar Pharmaceuticals, Inc.
  • Ignyta, Inc.
  • Lipocure Ltd.
  • MacroGenics, Inc.
  • Medicenna Therapeutics, Inc.
  • MEI Pharma, Inc.
  • Novartis AG
  • Novogen Limited
  • Progenics Pharmaceuticals, Inc.
  • Stemline Therapeutics, Inc.
  • 武田薬品工業

治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

最近のパイプライン動向

休止中のプロジェクト

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8191IDB

Summary

Global Markets Direct's, 'Medulloblastoma - Pipeline Review, H1 2016', provides an overview of the Medulloblastoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Medulloblastoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Medulloblastoma and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Medulloblastoma
  • The report reviews pipeline therapeutics for Medulloblastoma by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Medulloblastoma therapeutics and enlists all their major and minor projects
  • The report assesses Medulloblastoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Medulloblastoma

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Medulloblastoma
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Medulloblastoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Medulloblastoma Overview
  • Therapeutics Development
    • Pipeline Products for Medulloblastoma - Overview
    • Pipeline Products for Medulloblastoma - Comparative Analysis
  • Medulloblastoma - Therapeutics under Development by Companies
  • Medulloblastoma - Therapeutics under Investigation by Universities/Institutes
  • Medulloblastoma - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Medulloblastoma - Products under Development by Companies
  • Medulloblastoma - Products under Investigation by Universities/Institutes
  • Medulloblastoma - Companies Involved in Therapeutics Development
    • Bayer AG
    • DelMar Pharmaceuticals, Inc.
    • Ignyta, Inc.
    • Lipocure Ltd.
    • MacroGenics, Inc.
    • Medicenna Therapeutics, Inc.
    • MEI Pharma, Inc.
    • Novartis AG
    • Novogen Limited
    • Progenics Pharmaceuticals, Inc.
    • Stemline Therapeutics, Inc.
    • Takeda Pharmaceutical Company Limited
  • Medulloblastoma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (topotecan hydrochloride + vincristine sulfate) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dianhydrogalactitol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Edotreotide Labeled Yttrium 90 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • irinotecan hydrochloride + TBio-02 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LEQ-506 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MDNA-55 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies to Target IL13Ralpha2 and CD3 for Melanoma and Medulloblastoma - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies to Target ROR1 and CD3 for Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nifurtimox - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nifurtimox SR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • p28 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pracinostat - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • siomycin A - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SL-301 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Hedgehog Signaling for Medulloblastoma - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • taladegib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • THR-317 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Trilexium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VMY-1103 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Medulloblastoma - Recent Pipeline Updates
  • Medulloblastoma - Dormant Projects
  • Medulloblastoma - Product Development Milestones
    • Featured News & Press Releases
      • Mar 15, 2016: FDA Grants Second Orphan Designation For VAL-083
      • Feb 19, 2016: Novogen Patent Covering Trilexium Has Been Proceeded To Grant
      • Nov 11, 2015: DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Promising Potential Treatment for Pediatric Brain Tumors
      • Sep 19, 2011: Researchers Discover Regulatory Protein As Potential Drug Target For Brain Tumors
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Medulloblastoma, H1 2016
  • Number of Products under Development for Medulloblastoma - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Medulloblastoma - Pipeline by Bayer AG, H1 2016
  • Medulloblastoma - Pipeline by DelMar Pharmaceuticals, Inc., H1 2016
  • Medulloblastoma - Pipeline by Ignyta, Inc., H1 2016
  • Medulloblastoma - Pipeline by Lipocure Ltd., H1 2016
  • Medulloblastoma - Pipeline by MacroGenics, Inc., H1 2016
  • Medulloblastoma - Pipeline by Medicenna Therapeutics, Inc., H1 2016
  • Medulloblastoma - Pipeline by MEI Pharma, Inc., H1 2016
  • Medulloblastoma - Pipeline by Novartis AG, H1 2016
  • Medulloblastoma - Pipeline by Novogen Limited, H1 2016
  • Medulloblastoma - Pipeline by Progenics Pharmaceuticals, Inc., H1 2016
  • Medulloblastoma - Pipeline by Stemline Therapeutics, Inc., H1 2016
  • Medulloblastoma - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Medulloblastoma Therapeutics - Recent Pipeline Updates, H1 2016
  • Medulloblastoma - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Medulloblastoma, H1 2016
  • Number of Products under Development for Medulloblastoma - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top